Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 22803570)

1.

Glucocerebrosidase mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease.

Kurzawa-Akanbi M, Hanson PS, Blain PG, Lett DJ, McKeith IG, Chinnery PF, Morris CM.

J Neurochem. 2012 Oct;123(2):298-309. doi: 10.1111/j.1471-4159.2012.07879.x. Epub 2012 Aug 22.

2.

GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology.

Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Kukull W, Nelson PT, Jicha GA, Neltner JH, Galasko D, Masliah E, Trojanowski JQ, Schellenberg GD, Yearout D, Huston H, Fritts-Penniman A, Mata IF, Wan JY, Edwards KL, Montine TJ, Zabetian CP.

Neurology. 2012 Nov 6;79(19):1944-50. doi: 10.1212/WNL.0b013e3182735e9a. Epub 2012 Oct 3.

3.

Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains.

Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW, Schapira AH.

Ann Neurol. 2012 Sep;72(3):455-63. doi: 10.1002/ana.23614.

4.

Glucocerebrosidase, a new player changing the old rules in Lewy body diseases.

Yang NY, Lee YN, Lee HJ, Kim YS, Lee SJ.

Biol Chem. 2013 Jul;394(7):807-18. doi: 10.1515/hsz-2012-0322. Review.

PMID:
23435096
5.

Gaucher disease paradigm: from ERAD to comorbidity.

Bendikov-Bar I, Horowitz M.

Hum Mutat. 2012 Oct;33(10):1398-407. doi: 10.1002/humu.22124. Epub 2012 Jun 11. Review.

PMID:
22623374
6.

Glucocerebrosidase and Parkinson disease: Recent advances.

Schapira AH.

Mol Cell Neurosci. 2015 May;66(Pt A):37-42. doi: 10.1016/j.mcn.2015.03.013. Epub 2015 Mar 20. Review.

7.

Association of glucocerebrosidase mutations with dementia with lewy bodies.

Clark LN, Kartsaklis LA, Wolf Gilbert R, Dorado B, Ross BM, Kisselev S, Verbitsky M, Mejia-Santana H, Cote LJ, Andrews H, Vonsattel JP, Fahn S, Mayeux R, Honig LS, Marder K.

Arch Neurol. 2009 May;66(5):578-83. doi: 10.1001/archneurol.2009.54.

8.

The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism.

DePaolo J, Goker-Alpan O, Samaddar T, Lopez G, Sidransky E.

Mov Disord. 2009 Aug 15;24(11):1571-8. doi: 10.1002/mds.22538. Review.

9.

The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders.

Velayati A, Yu WH, Sidransky E.

Curr Neurol Neurosci Rep. 2010 May;10(3):190-8. doi: 10.1007/s11910-010-0102-x. Review.

10.

Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage.

Cleeter MW, Chau KY, Gluck C, Mehta A, Hughes DA, Duchen M, Wood NW, Hardy J, Mark Cooper J, Schapira AH.

Neurochem Int. 2013 Jan;62(1):1-7. doi: 10.1016/j.neuint.2012.10.010. Epub 2012 Oct 23.

11.

Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant.

Bendikov-Bar I, Ron I, Filocamo M, Horowitz M.

Blood Cells Mol Dis. 2011 Jan 15;46(1):4-10. doi: 10.1016/j.bcmd.2010.10.012. Epub 2010 Nov 23.

PMID:
21106416
12.

Lysosomal impairment in Parkinson's disease.

Dehay B, Martinez-Vicente M, Caldwell GA, Caldwell KA, Yue Z, Cookson MR, Klein C, Vila M, Bezard E.

Mov Disord. 2013 Jun;28(6):725-32. doi: 10.1002/mds.25462. Epub 2013 Apr 11. Review.

PMID:
23580333
13.

Glucocerebrosidase mutations in diffuse Lewy body disease.

Nishioka K, Ross OA, Vilariño-Güell C, Cobb SA, Kachergus JM, Mann DM, Snowden J, Richardson AM, Neary D, Robinson CA, Rajput A, Papapetropoulos S, Mash DC, Pahwa R, Lyons KE, Wszolek ZK, Dickson DW, Farrer MJ.

Parkinsonism Relat Disord. 2011 Jan;17(1):55-7. doi: 10.1016/j.parkreldis.2010.09.009.

PMID:
20971030
14.

Exploring the link between glucocerebrosidase mutations and parkinsonism.

Westbroek W, Gustafson AM, Sidransky E.

Trends Mol Med. 2011 Sep;17(9):485-93. doi: 10.1016/j.molmed.2011.05.003. Epub 2011 Jul 1. Review.

15.

Glucocerebrosidase mutations and the pathogenesis of Parkinson disease.

Beavan MS, Schapira AH.

Ann Med. 2013 Dec;45(8):511-21. doi: 10.3109/07853890.2013.849003. Review.

PMID:
24219755
17.

Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.

Yap TL, Gruschus JM, Velayati A, Westbroek W, Goldin E, Moaven N, Sidransky E, Lee JC.

J Biol Chem. 2011 Aug 12;286(32):28080-8. doi: 10.1074/jbc.M111.237859. Epub 2011 Jun 8.

18.

Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.

Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E, Cooper A, Garner B, Halliday GM.

Brain. 2014 Mar;137(Pt 3):834-48. doi: 10.1093/brain/awt367. Epub 2014 Jan 28.

19.

Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant β-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant.

Babajani G, Tropak MB, Mahuran DJ, Kermode AR.

Mol Genet Metab. 2012 Jul;106(3):323-9. doi: 10.1016/j.ymgme.2012.04.018. Epub 2012 Apr 26.

20.

Unfolded protein response in Gaucher disease: from human to Drosophila.

Maor G, Rencus-Lazar S, Filocamo M, Steller H, Segal D, Horowitz M.

Orphanet J Rare Dis. 2013 Sep 11;8:140. doi: 10.1186/1750-1172-8-140.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk